Refractory Cancer News and Research

RSS

Biotoxin from puffer fish may provide treatment for opioid withdrawal

On November 10, 2004 investigators involved in a Phase IIa clinical trial of the novel biotoxin Tetrodotoxin (TTX) for the treatment of opioid withdrawal enrolled their first participants.

18 Nov 2004

$Trial of a drug derived from the puffer fish for treatment of refractory cancer pain$

Trial of a drug derived from the puffer fish for treatment of refractory cancer pain

Investigators involved in the pivotal clinical trial of TectinTM enrolled and dosed the first of up to 150 patients that will participate in the study. It is one of the largest Canadian clinical trials to evaluate the efficacy and safety of a drug for treatment of medically refractory cancer pain, and will take place in up to 25 treatment centres across Canada.

11 May 2004

Data on pre-clinical activity of satraplatin in prostate cancer to be released

Spectrum Pharmaceuticals, Inc has announced that new data on pre-clinical activity of satraplatin in prostate cancer cell lines are being presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR) in Orlando, Florida.

29 Mar 2004